Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedApr 02, 2026
DataAggregated Company Financials
Companies1391
  • 7D1.2%
  • 3M-4.7%
  • 1Y5.5%
  • YTD-5.0%

In the last week, the Healthcare industry is up 1.2%, with Eli Lilly up 4.2%. Meanwhile, Boston Scientific actually underperformed within the industry, shrinking 11% in the last week. This means that the industry has gained 5.5% over the past year. Earnings are forecast to grow by 16% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 02 Apr 2026US$6.2tUS$3.3tUS$128.2b22.7x48x1.9x
Sat, 28 Feb 2026US$6.6tUS$3.3tUS$126.9b25.6x51.9x2x
Mon, 26 Jan 2026US$6.6tUS$3.2tUS$130.6b28.5x50.6x2.1x
Wed, 24 Dec 2025US$6.5tUS$3.2tUS$135.2b26.3x48.4x2x
Fri, 21 Nov 2025US$6.3tUS$3.2tUS$133.1b25x47.1x2x
Sun, 19 Oct 2025US$6.0tUS$3.1tUS$140.4b24.8x42.5x1.9x
Tue, 16 Sep 2025US$5.7tUS$3.1tUS$137.5b23.6x41.7x1.9x
Thu, 14 Aug 2025US$5.4tUS$3.1tUS$140.7b24.1x38.7x1.8x
Sat, 12 Jul 2025US$5.6tUS$3.0tUS$127.9b24.4x43.5x1.8x
Mon, 09 Jun 2025US$5.5tUS$3.0tUS$127.2b24x43.2x1.8x
Wed, 07 May 2025US$5.5tUS$2.7tUS$125.5b24.5x44.1x2x
Fri, 04 Apr 2025US$5.6tUS$2.6tUS$82.0b25.6x68.2x2.1x
Sun, 02 Mar 2025US$5.9tUS$2.6tUS$79.3b27.5x74x2.2x
Tue, 28 Jan 2025US$6.1tUS$2.9tUS$85.5b28.4x70.8x2.1x
Thu, 26 Dec 2024US$5.9tUS$2.9tUS$78.3b26.9x74.8x2x
Sat, 23 Nov 2024US$6.0tUS$2.9tUS$77.3b28.3x77.9x2.1x
Mon, 21 Oct 2024US$6.2tUS$2.8tUS$58.8b32.2x106.2x2.2x
Wed, 18 Sep 2024US$6.3tUS$2.8tUS$60.1b31.2x105.5x2.2x
Fri, 16 Aug 2024US$6.1tUS$2.8tUS$55.7b31.3x109.4x2.2x
Sun, 14 Jul 2024US$6.3tUS$2.8tUS$62.2b31.2x101.7x2.2x
Tue, 11 Jun 2024US$6.2tUS$2.8tUS$63.6b30x97.9x2.2x
Thu, 09 May 2024US$6.1tUS$2.8tUS$65.4b30.7x93.4x2.2x
Sat, 06 Apr 2024US$6.1tUS$2.8tUS$83.9b32.4x72.7x2.2x
Mon, 04 Mar 2024US$6.3tUS$2.8tUS$85.0b31.2x74.2x2.3x
Wed, 31 Jan 2024US$6.4tUS$2.8tUS$80.0b31.9x79.7x2.3x
Fri, 29 Dec 2023US$6.2tUS$2.8tUS$91.5b32.8x68x2.2x
Sun, 26 Nov 2023US$5.9tUS$2.8tUS$91.4b28.6x64.4x2.1x
Tue, 24 Oct 2023US$5.7tUS$2.8tUS$99.6b24.8x57.3x2x
Thu, 21 Sep 2023US$6.0tUS$2.8tUS$98.6b28.2x60.7x2.2x
Sat, 19 Aug 2023US$6.1tUS$2.8tUS$99.3b27.7x61.4x2.2x
Mon, 17 Jul 2023US$6.0tUS$2.7tUS$110.9b26.3x54x2.2x
Wed, 14 Jun 2023US$6.0tUS$2.7tUS$110.0b26x54.7x2.2x
Fri, 12 May 2023US$6.0tUS$2.7tUS$112.0b24.9x53.7x2.2x
Sun, 09 Apr 2023US$5.9tUS$2.5tUS$121.9b24.3x48.6x2.4x
Price to Earnings Ratio

48.6x


Total Market Cap: US$5.9tTotal Earnings: US$121.9bTotal Revenue: US$2.5tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 48.0x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 9.6% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market-0.32%
Healthcare1.21%
Pharma2.95%
Biotech2.28%
Life Sciences1.51%
Healthcare Services-0.18%
Medical Equipment-2.01%
Healthtech-3.72%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 55.8x.
    • Analysts are expecting annual earnings growth of 16.0%, which is higher than its past year's earnings growth of 5.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 23% over the next 5 years.
  • However this is lower than its past earnings growth rate of 40% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 11% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$954.524.2%
+US$34.2b		16.7%PE41.4x
ABBV AbbVieUS$214.983.8%
+US$13.8b		4.8%PE90.8x
JNJ Johnson & JohnsonUS$244.121.7%
+US$10.1b		57.1%PE21.9x
PFE PfizerUS$28.554.7%
+US$7.2b		15.6%PE21x
BMY Bristol-Myers SquibbUS$61.734.7%
+US$5.7b		3.6%PE17.9x

Latest News

COR
US$317.66
Cencora
7D
-2.3%
1Y
13.6%
VRTX
US$447.26
Vertex Pharmaceuticals
7D
-1.7%
1Y
-7.5%
LLY
US$954.52
Eli Lilly
7D
4.2%
1Y
16.7%
ISRG
US$464.45
Intuitive Surgical
7D
-1.2%
1Y
-8.4%
ABBV
US$214.98
AbbVie
7D
3.8%
1Y
4.8%
ABT
US$102.38
Abbott Laboratories
7D
-2.3%
1Y
-22.4%
MRK
US$120.84
Merck
7D
1.2%
1Y
39.5%
BSX
US$62.00
Boston Scientific
7D
-11.1%
1Y
-38.0%
JNJ
US$244.12
Johnson & Johnson
7D
1.7%
1Y
57.1%

Johnson & Johnson (JNJ): The $100 Billion Revenue Frontier and the MedTech Evolution

Johnson & Johnson (JNJ) is currently trading at $242.83 USD on the NYSE as of the afternoon session on March 30, 2026, reflecting a steady 1% gain for the day. After a transformative 2025 that saw the full integration of its "pure-play" healthcare strategy following the Kenvue spin-off, the company has entered 2026 with significant momentum.
RGC
US$33.72
Regencell Bioscience Holdings
7D
39.6%
1Y
5,345.6%
BMY
US$61.73
Bristol-Myers Squibb
7D
4.7%
1Y
3.6%
MDT
US$86.06
Medtronic
7D
-2.1%
1Y
-3.2%
HCA
US$474.75
HCA Healthcare
7D
-1.9%
1Y
36.8%

HCA: Future Upside Will Center On Georgia Medicaid SDP Earnings Support

HCA Healthcare's analyst price targets have moved higher by a broad range that stretches into the mid $600s, reflecting analysts' updated models around Georgia's newly approved $1.9b Medicaid SDP program and potential efficiency gains from AI that could influence valuation multiples. Analyst Commentary Recent Street research around HCA Healthcare centers on two themes that matter for valuation: the newly approved Georgia Medicaid SDP program and potential AI driven efficiency gains.
PFE
US$28.55
Pfizer
7D
4.7%
1Y
15.6%
INSM
US$164.86
Insmed
7D
11.7%
1Y
124.8%
DXCM
US$62.37
DexCom
7D
-6.7%
1Y
-8.5%

DXCM: AI Coaching And Buybacks Will Support Future Market Share Confidence

DexCom's fair value estimate edges up by about $0.27 as analysts fine tune assumptions on the discount rate, revenue growth, profit margin, and future P/E, following a mix of price target changes across the Street, including recent upward revisions toward $84 to $86 and a lower $71 target tied to competition concerns. Analyst Commentary Recent Street research on DexCom reflects a split view, with some firms nudging targets higher into the mid $80s and others pushing back toward the low $70s on competition concerns.